Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT06297226)

🧪 Interventions in This Study

• Arlocabtagene Autoleucel (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (52 Sites)

Showing the first 25 of 52 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• Banner MD Anderson Cancer Center — Gilbert, Arizona
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) — Los Angeles, California
• UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
• Colorado Blood Cancer Institute — Denver, Colorado
• Mayo Clinic in Florida — Jacksonville, Florida
• Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• Northside Hospital — Atlanta, Georgia
• Northwestern Memorial Hospital — Chicago, Illinois
• University of Chicago Medical Center — Chicago, Illinois
• University of Iowa — Iowa City, Iowa
• The University of Kansas Cancer Center - Westwood — Westwood, Kansas
• Norton Women's and Children's Hospital — Louisville, Kentucky
• Local Institution - 0065 — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
• Roswell Park Cancer Institute — Buffalo, New York
• Icahn School of Medicine at Mount Sinai — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.